目的 探討哌柏西利致不良反應(yīng)的發(fā)生規(guī)律和臨床表現(xiàn)特點(diǎn)，為其臨床安全用藥提供參考。方法 檢索中國(guó)知網(wǎng)、萬(wàn)方數(shù)據(jù)、維普網(wǎng)、PubMed、Web of Science文獻(xiàn)數(shù)據(jù)庫(kù)中建庫(kù)至2023年12月哌柏西利致不良反應(yīng)案例報(bào)道并進(jìn)行統(tǒng)計(jì)分析。結(jié)果 納入文獻(xiàn)40篇，涉及患者44例，均為女性且以60歲以上患者居多；發(fā)生時(shí)間為用藥后1 d～15個(gè)月，主要集中在前3個(gè)月內(nèi)（63.64%）；累及皮膚、呼吸系統(tǒng)、血液系統(tǒng)、神經(jīng)系統(tǒng)等全身多個(gè)器官/系統(tǒng)。33例患者經(jīng)停藥和/或?qū)ΠY處理后好轉(zhuǎn)，6例患者死亡，可見(jiàn)其潛在的致死風(fēng)險(xiǎn)。結(jié)論 臨床工作者應(yīng)重視哌柏西利致不良反應(yīng)的危害性，加強(qiáng)患者用藥監(jiān)護(hù)，確保臨床用藥安全。

Objective To investigate the occurrence pattern and clinical manifestation characteristics of adverse drug reactions caused by palbociclib, and to provide reference for its safe clinical use. Methods Case reports of adverse reactions caused by palbociclib were retrieved from CNKI, Wanfang Data, VIP, PubMed, and Web of Science literature databases from December 2023 and analyzed statistically. Results Forty literatures were included, involving 44 patients, all of whom were female and most of whom were over 60 years old. The occurrence time was from 1 d to 15 months after medication, mainly in the first 3 months (63.64%). Involving skin, respiratory system, blood system, nervous system and other body organs/systems. 33 patients improved after drug withdrawal and/or symptomatic management, and 6 patients died, indicating the potential risk of death. Conclusion Clinical workers should pay attention to the danger of adverse drug reactions caused by palbociclib, strengthen the monitoring of patients' medication, and ensure the safety of clinical medication.

R979.1

國(guó)家自然科學(xué)基金資助項(xiàng)目（82060674）